secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zeo ScientifiX, Inc. (ZEOX)
CIK:        0001557376
Form:       8-K
Filed at:   2023-06-21T23:59:59+00:00
Accession:  0001829126-23-004312
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organicell appoints Harry Leider, MD, MBA as CEO effective June 21, 2023
------------------------------------------------------------------------

- Dr. Leider most recently served as CMO/EVP at Gelesis, gaining FDA approval for Plenity and leading the company through a NYSE IPO.
- He previously was CMO/Group VP at Walgreens Boots Alliance, leading clinical programs and health analytics across the Fortune 50.
- As CEO, he will lead Organicell, a clinical-stage biopharma developing regenerative therapies from perinatal sources for chronic diseases.
- Dr. Leider has over 25 years of healthcare executive experience, including roles at Ameritox, and academic appointments at Johns Hopkins and Harvard.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557376/000182912623004312/0001829126-23-004312-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557376/000182912623004312/organicellreg_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-23-004312

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer